MAM
VMLY&R India elevates Pooja Jauhari to group CEO
Mumbai: Global brand and customer experience agency VMLY&R on Wednesday announced the appointment of Pooja Jauhari as chief executive officer, VMLY&R India across its group of companies. Based out of the agency’s Mumbai office, she will report to VMLY&R Asia co-CEO Tripti Lochan, who is based in Singapore.
Jauhari takes over from Anil Nair, who is moving on to pursue new opportunities. Nair joined VMLY&R in 2019 from Law & Kenneth Saatchi & Saatchi India, where he was CEO (digital) and managing partner. VMLY&R first welcomed Jauhari in 2020, as the CEO of The Glitch. The independent creative agency was acquired by WPP in 2017 and integrated into the VMLY&R network in November 2020.
In this new role, she will oversee the agency’s combined operations, including VMLY&R, The Glitch, VMLY&R Commerce and GTB, across its three offices in India – Mumbai, Delhi and Chennai – plus its service of clients across the Indian subcontinent, said the statement.
She is also tasked with further integration of the network’s creative excellence in India, with its very strong customer experience, commerce and data capabilities, into an integrated powerhouse focused on human centricity, diversity, inclusion & high performance, it added.
“Since welcoming The Glitch into the VMLY&R network in 2020, we are seeing that together with VMLY&R India, the whole is far greater than the sum of the parts,” said Tripti Lochan. “Pooja’s proven track record of having driven a gender-blind and positive influence approach, aligns perfectly with our ongoing vision towards ever-improving our own inclusivity and progressiveness. Combined with her track record in growing The Glitch to be one of India’s best-known agencies, producing work for clients both nationally and globally, we believe her elevation makes us even better at creating connected brands, driving business for our clients, and positively impacting the communities they live in.”
“We thank Anil for being a part of our continued growth in India, and wish him the very best in the next stage of his journey,” she further said.
Having started her marketing career at JWT two decades ago, Jauhari moved to Unilever and then Worldwide Media before joining The Glitch in 2013. There, she was instrumental to the agency’s success, leading its strategic planning, plus setting its goals and approach to both business and culture.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
